Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 ©2021 KARYOPHARM THERAPEUTICS INC. A Commercial -Stage Pharmaceutical Company Pioneering Novel Cancer Therapies September 2021
1 ©2021 KARYOPHARM THERAPEUTICS INC.
Novel Cancer Therapies
September 20212 ©2021 KARYOPHARM THERAPEUTICS INC. Forward -looking Statements and Other Important Information
This presentation contains forward -looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding Karyopharm’s
guidance onitsexpected cash runway ;expectations andplans relating toXPOVIO forthetreatment ofadult patients with relapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large B-cell
lymphoma andother hematologic malignancies andsolid tumors ;commercialization ofXPOVIO oranyofitsdrug candidates andthecommercial performance ofXPOVIO ;submissions to,andthereview and
potential approval ofselinexor by,regulatory authorities, including theCompany’s regulatory strategy, theanticipated availability ofdata tosupport such submissions, timing ofsuch submissions andactions by
regulatory authorities andthepotential availability ofaccelerated approval pathways ;theexpected design oftheCompany’s clinical trials ;andthetherapeutic potential ofandpotential clinical development
plans forKaryopharm's drug candidates, especially selinexor .Such statements aresubject tonumerous important factors, risks anduncertainties, many ofwhich arebeyond Karyopharm's control, thatmay
cause actual events orresults todiffer materially from Karyopharm's current expectations .Forexample, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO ;thatregulators will
grant confirmatory approval intheEuropean Union based ontheBOSTON study inadult patients with multiple myeloma ;orthatanyofKaryopharm’s drug candidates, including selinexor andeltanexor, will
successfully complete necessary clinical development phases orthatdevelopment ofanyofKaryopharm’s drug candidates willcontinue .Further, there canbenoguarantee thatanypositive developments in
thedevelopment orcommercialization ofKaryopharm’s drug candidate portfolio willresult instock price appreciation .Management’s expectations and, therefore, anyforward -looking statements inthispress
release could also beaffected byrisks anduncertainties relating toanumber ofother factors, including thefollowing :theriskthattheCOVID -19pandemic could disrupt Karyopharm’s business more severely
than itcurrently anticipates, including bynegatively impacting sales ofXPOVIO, interrupting ordelaying research anddevelopment efforts, impacting theability toprocure sufficient supply forthedevelopment
and commercialization ofselinexor orother product candidates, delaying ongoing orplanned clinical trials, impeding theexecution ofbusiness plans, planned regulatory milestones and timelines, or
inconveniencing patients ;theadoption ofXPOVIO inthecommercial marketplace, thetiming andcosts involved incommercializing XPOVIO oranyofKaryopharm’s drug candidates thatreceive regulatory
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
20 Pages
Nubeva